Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2017-03-31 was 0.00 shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-09-30 was 0.00 shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-06-30 was 0.00 shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-03-31 was 0.00 shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 279.07K shares, a 53.20% decline from fiscal 2018.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 596.27K shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 5.00K shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2014 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2019-12-31 | 279.07K shares 10-K · filed 2020-03-13 | |
| 2018-12-31 | 596.27K shares 10-K · filed 2020-03-13 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | |
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-10 | 5.00K shares derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-11 | 5.00K shares derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | 5.00K shares derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 5.00K shares 10-K · filed 2016-03-23 |
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-10 | 0.00 shares derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-11 | 0.00 shares derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-12 | 0.00 shares derived: sum of 4 quarters · filed 2016-05-12 |
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 0.00 shares 10-K · filed 2016-03-23 |
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-13 | |
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-13 | |
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-05-14 | |
| 2013-12-31 | 0.00 shares 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |